or Try an Advanced Search...

    ETF Components for IBB - iShares Nasdaq Biotechnology Index Fund


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    GILD A 0.78 8.62
    AMGN C -0.29 7.84
    VRTX D -1.02 7.62
    REGN F 0.64 7.21
    IQV F 1.62 4.13
    ALNY C 2.75 3.38
    MTD D 3.90 3.04
    BIIB F -0.12 2.70
    ARGX A 1.58 2.66
    BNTX B -1.43 2.32

    Represented by ETF Holdings

    Keywords: S&P 500 Biotechnology Medicine Nasdaq 100 Biopharmaceutical Inflammation Immunology Autoimmune Disease Autoimmune Disorders Bone Breakthrough Therapy Cardiovascular Disease Cholesterol Clinical Development Cystic Fibrosis Disease Hemophilia Immune Disorders Infection Infectious Diseases
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research

    Recent News for iShares Nasdaq Biotechnology Index Fund & its Holdings

    Date Stock Title
    Nov 1 VRTX Stocks to watch: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 BNTX Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 GILD Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 ARGX argenx downgraded at Baird as shares get pricey
    Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
    Nov 1 IQV IQVIA Holdings Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
    Nov 1 GILD Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
    Nov 1 REGN What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
    Nov 1 BIIB Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
    Nov 1 ALNY Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 1 REGN Regeneron Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
    Nov 1 BIIB Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
    Nov 1 AMGN Amgen Third Quarter 2024 Earnings: EPS Beats Expectations
    Nov 1 REGN Regeneron: Investors In Panic Mode On Increased Eylea Fears
    Nov 1 REGN Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
    Nov 1 IQV IQVIA Holdings Inc (IQV) Q3 2024 Earnings Call Highlights: Strong EPS Growth Amid Market Challenges
    Nov 1 ARGX argenx SE (ARGNF) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Challenges
    Nov 1 ALNY Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
    Nov 1 REGN Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...
    Nov 1 REGN Q3 2024 Regeneron Pharmaceuticals Inc Earnings Call
    The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc. The fund is non-diversified.
    Exchange Traded Fund ETF Stock Market Index Biotechnology Pharmaceutical Nasdaq Composite Index Industry Classification Nasdaq Biotechnology Index
    Back to the Main IBB Page...